Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18822510 | 0.85 | YAP1 (0.62) | YAP1KDM4EPKMGPR119STS | |
| SCHEMBL12249924 | 0.85 | YAP1 (0.62) | YAP1KDM4EPKMGPR119STS | |
| SCHEMBL24530131 | 0.84 | YAP1 (0.49) | YAP1CCR1GAA | |
| SCHEMBL19982213 | 0.82 | YAP1 (0.85) | YAP1GPR119GAA | |
| SCHEMBL19982212 | 0.82 | YAP1 (0.85) | YAP1GPR119GAA | |
| SCHEMBL29189817 | 0.82 | YAP1 (0.57) | YAP1KDM4EPKMGAA | |
| SCHEMBL29968272 | 0.82 | YAP1 (0.57) | YAP1KDM4EPKMGAA | |
| SCHEMBL7090242 | 0.81 | KDM4E (0.69) | YAP1KDM4EPKMGPR119STS | |
| SCHEMBL20556236 | 0.78 | YAP1 (0.60) | YAP1KDM4EPKMGPR119STS | |
| SCHEMBL18788023 | 0.78 | YAP1 (0.60) | YAP1KDM4EPKMGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10888561-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888561-B2 | CGRP receptor antagonists | CALCRL, CALCR, VIPR1 | YAP1 3907/4885KDM4E 3817/4885PKM 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.